Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA introduces a dedicated regulatory structure for psychedelic drug development, including MDMA

Vancouver, Canada, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biopharmaceutical company advancing non-hallucinogenic, psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders, including AUD, today announced an advancement of its IP portfolio with the publication in the United States of its patent application covering a novel combination of 3,4-methylenedioxymethamphetamine (“MDMA”) and N-acylethanolamines, such as palmitoylethanolamide (“PEA”), in methods of treating post-traumatic stress disorder (PTSD), anxiety, and eating disorders. The U.S. patent application was published by the United States Patent and Trademark Office (USPTO).